Female sexual arousal disorder FSAD is a disorder characterized by a persistent or recurrent inability to attain sexual arousal or to maintain arousal until the completion of a sexual activity.
The "Frigiditate sexuala" can also
Frigiditate sexuala to an inadequate lubrication -swelling response normally present arousal and sexual activity.
The condition should be distinguished from a general loss of interest in sexual activity and from other sexual dysfunctionssuch as the orgasmic disorder anorgasmia and hypoactive sexual desire disorderwhich is characterized as a lack or absence of sexual fantasies and desire for sexual activity for some period of time. Although female sexual dysfunction is currently a contested diagnostic, Frigiditate sexuala has become more common in recent years to use testosterone -based drugs off-label to treat FSAD.
While drug are technically not allowed to market these drugs for off-label uses, sharing the information with doctors at CME conferences has proved to be an effective way to navigate around Frigiditate sexuala FDA approval process.
A number of studies have explored Frigiditate sexuala factors that contribute to female sexual arousal disorder and female orgasmic disorder. These factors include both psychological and physical factors. Psychologically, possible causes of the disorder include the "Frigiditate sexuala" of childhood and adolescence experiences and current events — both within the individual and within the current relationship. There has been little investigation of the impact of individual factors on female sexual dysfunction.
Such factors include stress, levels of fatigue, gender identity, health, and other individual attributes and experiences, such as dysfunctional sexual beliefs  that may affect sexual desire or response.
Over exposure to pornography -style media is also thought to lead to poor body imageself-consciousness and lowered self-esteem. Sexual dysfunction can also occur secondary to major psychiatric disorders, including depression. A substantial body of research has explored the role of interpersonal factors in female sexual dysfunction, particularly in relation to orgasmic response. These studies have
Frigiditate sexuala focused on the impact of the quality of the relationship on the sexual functioning of the partners.
Some studies have evaluated the role of specific relationship variables, whereas others have examined overall relationship satisfaction. Subject populations have varied from distressed couples to sexually dysfunctional clients to those in satisfied relationships.
The disorders most likely to result in sexual dysfunction are those that lead to problems in circulatory or neurological function. These factors have been more extensively explored in men than in women. Physical etiologies such as neurological and cardiovascular illnesses have been directly implicated in both premature and retarded Frigiditate sexuala as well as in erectile disorder,  but the contribution of physiological factors to female sexual dysfunction is not so clear.
However, recent literature does suggest that there may be an impairment in the arousal phase "Frigiditate sexuala" diabetic women. In fact, the lack of a clear association between medical disorders and sexual functioning suggests that psychological factors play a significant part in the impact of these disorders on sexual functioning.
In a small pilot study of four women with female sexual arousal disorder, Maravilla reported there was less brain activation seen in this group, including very little activation in the amygdala.
These women also showed increased activation in the temporal areas, in contrast to women without sexual difficulties, who showed deactivation in similar areas. This may suggest an increased level of inhibition Frigiditate sexuala an arousal stimulus in this small group of women with FSAD. Several types of medications, including selective serotonin
Frigiditate sexuala inhibitors SSRIscan cause sexual dysfunction and in the case of SSRI and SNRI, these dysfunctions may become permanent after the end of the treatment.
Kaplan proposed that sexual dysfunction was based on intrapsychic, interpersonal, and behavioural levels. The DSM-5 lists the diagnostic criteria as including a minimum of three of the following: Difficulties arise with this definition in terms of what constitutes an adequate lubrication-swelling response.
There is no "gold standard" regarding the length of time it should take to become aroused or the level of arousal that should be achieved. There may also Frigiditate sexuala differences in physiological and subjective levels of arousal, with some women reporting no feelings of sexual arousal despite evidence of vaginal vasocongestion and others reporting arousal in the absence of such evidence. The expectations and past experiences of clinicians and clients may also lead them to classify the same symptoms as female sexual
Frigiditate sexuala disorder in one woman but not in another.
There are several subtypes of female sexual arousal disorders. They may indicate onset: They may be based on context: For example, the disorder may occur with a spouse but not with a different partner.
The length of time the disorder has existed and the extent to which it is partner- or situation-specific, as opposed to occurring in all situations, may be the result of different causative factors and may influence the treatment for the disorder. It may be due to psychological factors or a combination of factors. The FDA has approved one medication for the treatment of disorders of female libido, flibanserin.
One problem with the current "Frigiditate sexuala" in the DSM-IV  is that subjective arousal is not included. There is often no correlation between women's subjective and physiological arousal. The Frigiditate sexuala sub-type is the most common in clinical settings .
One of the largest criticisms for female sexual arousal disorder is whether it is an actual disorder or an idea put forth by pharmaceutical companies in order to step into a potentially billion dollar industry; see Orgasm Inc. Of the handful of questions, if any respondent answered yes at any time, they were classified as having FSD. Here are the questions asked that respondents could only choose a response of Yes or No: Furthermore, the author Edward O. Laumann turned out to have financial ties to Pfizercreator of Viagra.
Another criticism, for example, is that "the meaningful benefits of experimental drugs for women's sexual difficulties are questionable, and the financial conflicts of interest of experts who endorse the notion of a highly prevalent medical condition are extensive. Professor of bioethics and sociology Jennifer R. Fishman argues that the categorization of female sexual dysfunction as a treatable disease has only been made possible through the input of academic clinical researchers.
Through ethnographic research, she believes she has shown how academic clinical researchers have provided the scientific research needed by pharmaceutical companies to bio-medicalize female sexual dysfunction and consequently identify a market of consumers for it.
She questions the professional ethics of this exchange network between researchers and pharmaceutical companies, as the clinical research trials are funded by pharmaceutical companies and researchers are given considerable financial rewards for their work. She argues that the conferences where definition of Frigiditate sexuala disease and diagnostic criteria are defined "Frigiditate sexuala" research is presented to clinicians are also ethically ambiguous, as they are funded by pharmaceutical companies.
It is also worth noting that female sexual arousal disorder is rarely a solitary diagnosis. Due to its high rates of comorbidity with hypoactive sexual desire disordera new disorder is being proposed for the DSM Heather Hartely of Portland State University, Oregon is critical of the shift from female sexual dysfunction being Frigiditate sexuala as an arousal problem to a desire problem. In her article, "The 'Pinking' of Viagra Culture", she Frigiditate sexuala that the change from
Frigiditate sexuala sexual arousal disorder to hypoactive sexual desire disorder is indicative of "disease mongering" tactics by the drug industry through an effort to match up a drug to some subcomponent of the DSM classification.
Additionally, Leonore Tiefer of NYU School of Medicine voiced concerns that the success of Viagra, in combination with feminist rhetoric, were being used as a means of fast-tracking public acceptance of pharmaceutical treatment of female sexual arousal disorder.
The justification behind this, she says, is that "the branding of Viagra has succeeded so thoroughly in rationalizing the idea of sexual correction and enhancement through pills that Frigiditate sexuala seems inevitable and only fair that such a product be made available for women," giving a dangerous appeal to "nonapproved drugs though off-label prescribing".
Natural variation could be overlooked because there are no specific duration or severity criteria for diagnosis. From Wikipedia, the free encyclopedia.
For other uses, see Hypoactive sexual desire disorder. This article includes a list of referencesbut its sources remain unclear because it has insufficient inline citations. Please help to improve this article by introducing more precise citations. February Learn how Frigiditate sexuala when to remove this template message.
This section needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. August Learn how and when to remove this template message. Parts of this article those related to DSM-V update in need to be updated. Please update this article to reflect recent events or newly available information. Journal of Sex Research. American Psychiatric Publishing, Inc.
Hormones and Primate Sexual Motivation". Nature Reviews Drug Discovery. Retrieved 3 October A brief review and discussion of sex differences in the specificity of sexual arousal".
Sexual and Relationship Therapy. Retrieved 15 December The Commodification of Female Sexual Dysfunction". Social Studies of Science. Archives of Sexual Behavior. Retrieved 14 December Retrieved 1 April A brief review that explores issues of the medicalization of the female orgasm "Female Sexual Dysfunction: Archived from the original on Female diseases of the pelvis and genitals N70—N99— Endometriosis of ovary Female infertility Anovulation Poor
Frigiditate sexuala reserve Mittelschmerz Oophoritis Ovarian apoplexy Ovarian cyst Corpus luteum cyst Follicular cyst of ovary Theca lutein cyst Ovarian hyperstimulation syndrome Ovarian torsion.
Female infertility Fallopian tube obstruction Hematosalpinx Hydrosalpinx Salpingitis. Asherman's syndrome Dysfunctional uterine bleeding Endometrial hyperplasia Endometrial polyp Endometriosis Endometritis. Female infertility Recurrent miscarriage. Cervical dysplasia Cervical incompetence Cervical polyp Cervicitis Female infertility Cervical stenosis Nabothian cyst.
Dyspareunia Hypoactive sexual desire disorder Sexual arousal disorder Vaginismus. Vaginal bleeding Postcoital bleeding. Pelvic congestion syndrome Pelvic inflammatory disease. Bartholin's cyst Kraurosis vulvae Vestibular papillomatosis Vulvitis Vulvodynia.
Persistent genital arousal disorder. Delirium Post-concussion syndrome Organic brain syndrome. Psychoactive substances, substance abuse and substance-related disorders. Frigiditate sexualaschizotypal and delusional. Posts about Frigiditate written by Cezar. a pacientilor cu tulburari din sfera se adreseaza urologilor, ginecologilor sau psihologilor. De unde vine Titan premium pareri frigiditate sexuală?
Depresie severă, tulburări de relații, probleme sexuale a partenerului, boli (de. Cauzele frigiditate sexuală. Anul trecut. Și organul de control al drogurilor, produsele alimentare (pe scurt, de control), a permis pentru prima.
MORE: Abstinenta sexuala